On Tuesday we reported about oral arguments before a federal appeals court in Philadelphia in AstraZeneca, Novo Nordisk, and Sanofi’s lawsuits challenging federal agency findings that the companies’ conditions on 340B covered entities’ use of contract pharmacies violate the 340B statute.
Today we follow up with highlights and analysis from the exchanges between judges and lawyers during the hearing.
Today 340B Report takes a closer look at Tuesday's oral arguments in federal circuit court in Philadelphia in three key 340B contract pharmacy lawsuits.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
